Inovio Pharmaceuticals (GBM) Stock Overview

A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More details

GBM fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 99.1% below our estimate of its fair value

Revenue is forecast to grow 52.5% per year

Earnings have grown 23.6% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the German market

+ 1 more risk

GBM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW477,830 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

477,830 investors already sharing narratives

View all narratives

Inovio Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Inovio Pharmaceuticals
Historical stock prices
Current Share Price	US$0.59
52 Week High	US$2.48
52 Week Low	US$0.56
Beta	1.51
1 Month Change	-42.27%
3 Month Change	-52.63%
1 Year Change	-51.97%
3 Year Change	-87.91%
5 Year Change	-99.40%
Change since IPO	-98.18%

Recent updates

Shareholder Returns

	GBM	DE Biotechs	DE Market
7D	5.2%	-4.5%	2.2%
1Y	-52.0%	4.4%	3.5%

Return vs Industry: GBM underperformed the German Biotechs industry which returned 4.4% over the past year.

Return vs Market: GBM underperformed the German Market which returned 3.5% over the past year.

Price Volatility

Is GBM's price volatile compared to industry and market?
GBM volatility
GBM Average Weekly Movement	10.9%
Biotechs Industry Average Movement	6.8%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: GBM's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: GBM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1983	112	Jacqueline Shea	www.inovio.com

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial.

Inovio Pharmaceuticals, Inc. Fundamentals Summary

How do Inovio Pharmaceuticals's earnings and revenue compare to its market cap?
GBM fundamental statistics
Market cap	€63.34m
Earnings (TTM)	-€73.45m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Is GBM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GBM income statement (TTM)
Revenue	US$0
Cost of Revenue	US$52.19m
Gross Profit	-US$52.19m
Other Expenses	US$32.75m
Earnings	-US$84.93m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 12, 2026

Earnings per share (EPS)	-0.77
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did GBM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/09 06:55
End of Day Share Price	2026/08/07 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inovio Pharmaceuticals, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Aydin Huseynov	Benchmark Company
Geoffrey Meacham	BofA Global Research
Raghuram Selvaraju	H.C. Wainwright & Co.

Inovio Pharmaceuticals (GBM) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Inovio Pharmaceuticals, Inc. Competitors

Novogenia

2invest

Dextech Medical

Biomark Diagnostics

Price History & Performance

Recent News & Updates

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Inovio Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 13, 2026

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 20, 2026

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.

Recent updates

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Inovio Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 13, 2026

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 20, 2026

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Inovio Pharmaceuticals, Inc. to Report Q4, 2025 Results on Mar 12, 2026

Pomerantz Law Firm Announces the Filing of A Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers

Forecast to breakeven in 2028

Inovio Pharmaceuticals, Inc. Announces that FDA Accepts for Review INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

New major risk - Share price stability

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $25.0002 million.

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

Inovio Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 10, 2025

Inovio Announces Clinical Proof-Of-Concept Data for Dna-Encoded Monoclonal Antibodies (Dmabs) Published in Nature Medicine

Inovio to Begin Rolling Submission of Bla for Ino-3107 for the Treatment of Rrp in Adults

INOVIO Announces Publication of Data from A Retrospective Study Investigating the Long-Term Clinical and Safety Response of Patients Treated with INO-3107

Inovio Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $25.000001 million.

Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from Russell Small Cap Completeness Index

Inovio Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 13, 2025

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 20, 2025

Inovio Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Inovio Pharmaceuticals, Inc. Announces Promising Interim Results from Ongoing Proof-Of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Inovio Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 18, 2025

INOVIO Announces Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as A Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

INOVIO Announces New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Third quarter 2024 earnings released: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

New major risk - Financial position

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.19 loss per share (vs US$1.61 loss in 2Q 2023)

Inovio Pharmaceuticals, Inc. Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

INOVIO Appointsof Steven Egge as Chief Commercial Officer

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million.

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: US$6.09 loss per share (vs US$14.07 loss in FY 2022)

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.15 loss in 3Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.46 loss in 2Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.36 loss in 1Q 2022)

INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)

Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.29 loss in 3Q 2021)

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800